As part of our ongoing series focussing on medications available in Australia, we have added a product review of avalglucosidase alfa for long-term enzyme replacement therapy for the treatment of Pompe disease in patients aged one year or older.
This review discusses pharmacological properties, mechanism of action and major studies featuring avalglucosidase alfa. It also provides commentary and recommendations from Dr Robert Henderson, senior staff specialist in Neurology at the Royal Brisbane and Women’s Hospital and The Prince Charles Hospital, and an Associate Professor at the University of Queensland.
Please login below to download this issue (PDF)